Summary Table of Actions
| Action Plan | Action party | Timeline | |
|---|---|---|---|
| Strategy 1: Awareness | |||
| 1.1 Awareness campaign for the general population | |||
| 1.1.1 | Revamp the website of Viral Hepatitis Control Office to provide up-to-date information and to improve user experience | DH | Completed |
| 1.1.2 | Review and update the information of the website of Viral Hepatitis Control Office | DH | 2023Q2 |
| 1.1.3 | Define yearly themes of awareness campaign across the territory | SCVH | Completed for 2020-22 |
| 1.1.4 | Establish the yearly theme for 2023 – 2024 | DH | 2022Q4 |
| 1.1.5 | Launch enhanced awareness campaign, involving Kwai Tsing District Health Centre | DH & DHC | 2020Q3 |
| 1.2 Professional training for healthcare workers | |||
| 1.2.1 | Conduct professional training programmes with the KAP assessment by phases, starting for obstetricians and midwives and extending to other groups of healthcare workers under the similar framework | HA, DH & constituent Colleges of Hong Kong Academy of Medicine | Yearly |
| 1.3 Education targeting at-risk populations, patients and their service providers | |||
| 1.3.1 | Develop focused education materials for pregnant women about preventive strategies of perinatal HBV transmission | DH & HA | 2020Q4 |
| 1.3.2 | Integrate education on safe injection and safer sex practices for prevention of HBV and HCV infection with HIV prevention programme | DH | Ongoing |
| 1.3.3 | Develop standardised training and education materials on HCV infection for service providers of PWID | DH, HA & NGOs | 2022Q1 |
| 1.4 Building a supportive environment | |||
| 1.4.1 | Enhance service capacity of testing and treatment for HBV and HCV infection | DH & HA | Ongoing |
| 1.4.2 | Evaluate HBV- and HCV-related service in the public sector to provide useful statistics and support the longer term planning and capacity building | HA | Ongoing |
| Action Plan | Action party | Timeline | |
|---|---|---|---|
| Strategy 2: Surveillance | |||
| 2.1 | Continue surveillance of viral hepatitis and hepatitis B vaccination coverage | DH | Ongoing |
| 2.2 | Develop a set of local indicators for monitoring and evaluation of the viral hepatitis elimination strategies for HBV and HCV infection | SCVH | Completed |
| 2.3 | Update the HBV and HCV situation according to the results of the Population Health Survey (PHS) | DH | 2022Q4 |
| 2.4 | Adopt a consistent and sustainable approach for the measurement of the Local Indicators for 2015 and 2020 | DH & HA | Ongoing |
| Action Plan | Action party | Timeline | |
|---|---|---|---|
| Strategy 3:Prevention | |||
| 3.1 Reduce mother-to-child transmission of HBV | |||
| 3.1.1 Using antivirals to prevent MTCT of HBV | |||
| 3.1.1.1 | Establish a policy initiative to provide HBsAg-positive mothers with high viral load with a treatment option to use antivirals | SCVH | Completed |
| 3.1.1.2 | Refer all HBsAg-positive mothers in HA for care of HBV infection | HA | 2021Q1 |
| 3.1.1.3 | Start using antivirals to prevent MTCT in selected HA hospitals as pilot | HA | 2020Q1 |
| 3.1.1.4 | Start using antivirals to prevent MTCT in all HA birthing hospitals | HA | 2020Q3 |
| 3.1.1.5 | Provide professional training to specialists in O&G, public and private, about the use of antivirals to prevent MTCT | DH & HA | 2021Q2 |
| 3.1.1.6 | Review the acceptance of using antivirals to prevent MTCT | DH & HA | 2022Q2 |
| 3.1.2 Post-vaccination serologic testing | |||
| 3.1.2.1 | Establish a policy initiative to provide PVST to babies born to HBsAg-positive mothers | SCVH | Completed |
| 3.1.2.2 | Establish the implementation plan and resources implication of PVST | DH & HA | 2020Q4 |
| 3.1.2.3 | Provide professional training about PVST programme to obstetricians and paediatricians | DH & HA | 2021Q3 |
| 3.1.2.4 | Establish the logistics and workflow of PVST | DH & HA | 2021Q4 |
| 3.1.2.5 | Implement PVST programme | DH & HA | 2022Q1 |
| 3.1.2.6 | Review the acceptance of PVST programme | DH & HA | 2023Q2 |
| 3.2 Prevent healthcare-related transmission of HBV and HCV | |||
| 3.2.1 | Screen all blood donations in a quality-assured manner | HA | Ongoing |
| 3.2.2 | Provide treatment to people contracted HCV through blood / blood product transfusion | HA | Ongoing |
| 3.2.3 | Conduct regular infection control training, including Standard Precautions and sharps injury or mucosal contact prevention and management | DH & HA | Ongoing |
| 3.3 Reduce risk and disease burden in vulnerable populations | |||
| 3.3.1 | Intensify condom programming and take harm reduction approach | DH | Ongoing |
| Action Plan | Action party | Timeline | |
|---|---|---|---|
| Strategy 4: Treatment | |||
| 4.1 Enhancement of treatment for HBV infection | |||
| 4.1.1 | Augment diagnosis and treatment capacity for HBV infection, in terms of laboratory, equipment, drug and model of care | HA | Ongoing |
| 4.1.2 | Review the service provided by nurse clinics | HA | 2022Q4 |
| 4.1.3 | Engage HA hepatologists to explore strategies to enhance service capacity for HBV infection in both public and private settings | DH & HA | 2021Q2 |
| 4.1.4 | Engage primary care physicians to support management of HBV infection | DH & HA | 2021Q4 |
| 4.1.5 | Develop information resources to facilitate management of HBV infection by primary care physicians | DH & HA | 2023Q1 |
| 4.1.6 | Promulgate the information resources to primary care physicians | DH & HA | 2023Q3 |
| 4.1.7 | Estimate the service need of ultrasound for HCC surveillance | DH & HA | 2021Q2 |
| 4.2 Expansion of access to direct-acting antivirals for HCV | |||
| 4.2.1 | Establish a policy initiative to deploy DAA in HCV treatment in a stepwise manner | HA | Completed |
| 4.2.2 | Expand DAA treatment for hepatitis C patients with METAVIR fibrosis stages F2 or above | HA | Completed |
| 4.2.3 | Expand DAA treatment for all hepatitis C patients | HA | 2021Q4 |
| 4.2.4 | Review the number of patients treated with DAA | HA | 2023Q1 |
| 4.3 Micro-elimination of HCV infection | |||
| 4.3.1. Screen and treat patients with end stage renal failure on dialysis | |||
| 4.3.1.1 | Establish a policy initiative to provide DAA for HCV treatment in all patients undergoing dialysis | SCVH | Completed |
| 4.3.1.2 | Start using DAA to treat HCV infection in all patients undergoing dialysis | HA | 2020Q1 |
| 4.3.2. Screen and treat patients co-infected with human immunodeficiency virus | |||
| 4.3.2.1 | Establish a policy initiative to provide DAA for HCV treatment in all HIV-positive patients | SCVH | Completed |
| 4.3.2.2 | Start using DAA to treat HCV infection in all patients co-infected with HIV | DH & HA | 2020Q4 |
| 4.3.2.3 | Review the number of patients co-infected with HCV and HIV treated with DAA | DH & HA | 2023Q2 |
| 4.3.2.4 | Assess the number of re-infection among patients co-infected with HCV and HIV after completion of effective HCV treatment | DH & HA | 2024Q2 |
| 4.4 Promotion of HCV testing in people who inject drugs | |||
| 4.4.1 | Establish a policy initiative to promote HCV testing in PWID, who are attending methadone clinics (MCs) or under the custody of Correctional Services Department, for treatment | SCVH | Completed |
| 4.4.2 | Provide specific educational information about HCV transmission, testing and treatment to PWID | DH | 2021Q1 |
| 4.4.3 | Engage professional staff and other workers serving PWID at MCs by promoting the importance of HCV infection | DH | 2021Q2 |
| 4.4.4 | Identify testing options and algorithms for HCV testing, including the carrying out of a pilot programme, at MCs | DH | 2021Q4 |
| 4.4.5 | Educate and engage staff of Correctional Services Department | DH & CSD | 2021Q4 |
Last revision date: 16 September 2021